



May 19, 2022

BSE Limited  
Scrip code: 535755

National Stock Exchange of India Limited  
Symbol: ABFRL

Sub.: Newspaper advertisement regarding financial results of Aditya Birla Fashion and Retail Limited ["the Company"] for the quarter and year ended March 31, 2022

- Ref.: 1. Regulation 30 & 47(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI Listing Regulations"]  
2. ISIN: INE647001011  
3. Our intimation dated May 18, 2022

Dear Sir/ Madam,

Pursuant to the above referred, please find enclosed the copies of the advertisement with respect to the financial results of the Company for the quarter and year ended March 31, 2022 as published in the following newspapers:

- (i) Business Standard [English – All Editions]; and  
(ii) Navshakti [Marathi – Mumbai Edition].

The same are also available on website of the Company i.e. at [www.abfrl.com](http://www.abfrl.com)

This is for your information and record.

Sincerely,

For **Aditya Birla Fashion and Retail Limited**

**Geetika Anand**  
Digitally signed  
by Geetika Anand  
Date: 2022.05.19  
12:49:15 +05'30'

**Geetika Anand**  
**Company Secretary and Compliance Officer**

Encl.: a/a

**ADITYA BIRLA FASHION AND RETAIL LIMITED**

**Registered Office:**

Piramal Agastya Corporate Park, Building 'A',  
4<sup>th</sup> and 5<sup>th</sup> Floor, Unit No. 401, 403, 501, 502,  
L.B.S. Road, Kurla, Mumbai - 400 070

**CIN:** L18101MH2007PLC233901  
**Tel.:** +91 86529 05000  
**Fax:** +91 86529 05400

**Website:** [www.abfrl.com](http://www.abfrl.com)

**E-mail:** [secretarial@abfrl.adityabirla.com](mailto:secretarial@abfrl.adityabirla.com)

July 22, the company said in a stock exchange filing. Dutta was appointed CFO in 2020. Incidentally, the term of Executive Director Rajiv Tandon comes to an end on July 21. He was responsible

for the firm's finances.

ITC's financial performance beat Bloomberg estimates of revenue of ₹15,983.9 crore and net income of ₹4,003.7 crore.

mix and pricing actions.

Besides, reopening of educational institutions helped in the recovery of the stationery business, though it was still below pre-pandemic levels.



## ADITYA BIRLA FASHION AND RETAIL LIMITED

[CIN: L18101MH2007PLC233901]

Piramal Agastya Corporate Park, Building 'A', 4th and 5th Floor, Unit No. 401, 403, 501, 502, L.B.S. Road, Kurla, Mumbai - 400 070  
Tel.: +91 86529 05000; Fax: +91 86529 05400 | E-mail: secretarial@abfrl.adityabirla.com Website: www.abfrl.com

### EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

(₹ in Crores)

Particulars	Quarter ended March 31, 2022 (Audited)	Quarter ended December 31, 2021 (Unaudited)	Quarter ended March 31, 2021 (Audited)	Year ended March 31, 2022 (Audited)	Year ended March 31, 2021 (Audited)
	2,282.83	2,987.10	1,821.58	8,136.22	5,248.92
and Exceptional items	44.63	269.45	(121.57)	(144.93)	(837.54)
er Exceptional items	44.63	269.45	(121.57)	(144.93)	(837.54)
Exceptional items	31.90	196.80	(195.86)	(118.36)	(736.00)
Comprising Profit/ (Loss) for the period (after tax)	33.55	197.11	(192.33)	(116.31)	(734.19)
	938.29	938.04	915.05	938.29	915.05
				1,835.01	1,728.72
(st)				2,773.32	2,643.79
				1,158.77	1,059.18
es				0.51	0.51
	0.17	-	0.22	0.17	0.22
Continued operations	0.47	2.03	(1.57)	(1.18)	(8.23)
	0.47	2.02	(1.57)	(1.18)	(8.23)
	2.53	6.53	(0.25)	0.04	(0.67)
	2.95	8.30	(0.55)	0.14	(1.83)

Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on May 18, 2022.

Quarter and year ended March 31, 2022 are not comparable with quarter and year ended March 31, 2021 pursuant to the acquisition of subsidiaries (Sabyasachi Calcutta Fashion Retail Private Limited w.e.f. March 26, 2021) and Joint Venture (Goodview Fashion Private Limited w.e.f. March 19, 2021) by the Group during the quarter ended

On dated July 24, 2020, issued an amendment to Ind AS 116 - Leases, by inserting a practical expedient w.r.t. "Covid-19-Related Rent Concessions" effective from the effective date of notification dated June 18, 2021, extended practical expedient upto June 30, 2022. The Group has applied the practical expedient with effect from April 01, 2020. The Group has also recorded rent concessions against rent expenses, to the extent available, and balance has been presented under "Other Income" as follows:

(₹ in Crores)

Particulars	Quarter ended			Year ended	
	March 31, 2022 (Audited)	December 31, 2021 (Unaudited)	March 31, 2021 (Audited)	March 31, 2022 (Audited)	March 31, 2021 (Audited)
Income from rent concessions, to the extent available	22.16	54.72	18.92	219.18	343.72
Income from rent concessions for periods beyond	-	2.61	-	-	0.48

The Company has approved fund raising by way of a Rights Issue. On June 25, 2020, it further approved the terms of the issue i.e. 9,04,65,693 equity shares of face value of ₹10 each ("RES") of face value of ₹100 per RES), aggregating to ₹995.12 Crore, in the ratio of 9 RES for every 77 existing fully-paid shares held by the eligible equity shareholders as follows: On July 28, 2020, 9,02,77,042 RES of face-value ₹10 each were allotted as Partly paid shares ("PPS") to the eligible applicants who paid the application amount of ₹10 each. The remaining 1,88,651 RES has been kept in abeyance, pending regulatory/ other clearances. c) First Call: On January 11, 2021, the 'First call' money of ₹27.50 per PPS was received. On February 18, 2021, ₹8,99,09,500 PPS, the amount due, was successfully received. 3,67,542 PPS were forfeited due to non-payment, in accordance with the Articles of Association and the Memorandum of Association. d) Final Call: On July 5, 2021, the final call money of ₹27.50 per PPS (including premium of ₹25) was called for and the payment period ended on July 19, 2021. The Company has issued a notice to those shareholders who were yet to pay the amount due, thereby allowing time until February 28, 2022. This period has been further extended to May 31, 2022. e) On May 31, 2021, the Board of Directors approved annulment of 3,67,542 partly paid-up shares ("PPS") which were earlier forfeited. The Company has received payment towards the said PPS on May 31, 2022 to remaining shareholders. f) There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the LoF. g) Pursuant to the provisions of the Companies Act, 2013, the financial results for the relevant previous period have been restated for the bonus element in respect of the aforesaid Rights Issue.

The Company has acquired exclusive online and offline rights to the global brand 'Reebok' for the Indian market and other ASEAN countries and purchase of certain assets of 'Reebok' including trademarks/liabilities by way of entering into a Licensing Agreement and a Purchase Agreement, respectively. As part of the transfer of global ownership of 'Reebok', various other assets of 'Reebok' including the brand 'Reebok', US and Adidas. The transaction will be effective upon signing of definitive agreement(s) and necessary statutory approvals, if any.

The Company has acquired a majority stake in HMLPL ("HMLPL"): On January 14, 2022, the Board of Directors approved the acquisition of majority stake in HMLPL by way of entering into a definitive agreement, completion of closing conditions precedent to be set out in the definitive agreements and statutory approvals, if any. HMLPL houses apparel, non-apparel business under the brand 'Masaba'. The Board of Directors at its meeting held on May 18, 2022 have noted, completion of the said conditions and authorised officers of the Company to proceed with the acquisition by signing definitive agreements, post which the Company will hold 52.4% stake in HMLPL making it a subsidiary of the Company.

The Company has reported COVID-19 as evident so far in above published financial results. With a large section of the population being vaccinated and evolving impact of the pandemic, management expects a material impact on the future operations of the Group. Management will continue to closely monitor any material changes to future economic conditions which



#### PRESS TRUST OF INDIA

Mumbai, 18 May

The country's largest domestic budget carrier, IndiGo, on Wednesday announced the appointment of Pieter Elbers as its chief executive officer, replacing incumbent Ronojoy Dutta, who is set to retire on September 30.

The 71-year-old Dutta, who came to helm the airline in January 2019, has decided to retire after guiding the airline through the turbulent Covid-19 period, IndiGo said in a statement.

Elbers' appointment, which is subject to regulatory approvals, will be effective from or before October 1, it said.

Since 2014, Elbers (52) has served as the president and CEO of KLM Royal Dutch Airlines.

He is also a member of the executive committee of the Air France-KLM Group, the airline said.

"We are thrilled to announce the appointment of Pieter Elbers as the chief executive officer of the company. India promises to be the last bastion of enormous growth globally and given Elbers' deep understanding of the business, his legendary leadership qualities coupled with his energy and passion, we are

## Novo Nordisk launches once-a-week insulin Icodec to India

#### SOHINI DAS

Mumbai, 18 May

Novo Nordisk, the leader in the Indian insulin market, has announced the launch of its novel insulin Icodec, which needs to be taken only once a week.

Speaking to Business Standard, Vikrant Shrotriya, vice-president for India, said India is one of the key markets for the Danish drug major, and it will continue to bring more drugs here.

He added that the products are first launched in India and then in the US and parts of Europe. However, the products will come to India within six-12 months of their launch.

Icodec, for example, is in phase-3 clinical trials, and the firm announced headline results from its phase-3 trial, achieving its primary endpoint of demonstrating non-inferiority in reducing blood glucose (HbA1c) at week 26.

If this insulin is available globally next year, then India will also have it soon. As such, Shrotriya said Indian patients will benefit from the global trial, and this should make the process of the Indian regulator's approval easier. "India is most of the global trials. We have around 200 clinical trial centres in India and ongoing here," he said.

He added that Novo Nordisk will also bring its obesity drug to India. India's insulin market is estimated to be around ₹1,000 crore and is growing at an annual growth rate of 10 per cent. India's oral diabetes market is clocking at a CAGR of 11 per cent. Torrent Pharma and Novo Nordisk in Gujarat from the crystals that are imported to India.

India is estimated to have 77 million diabetics, most of whom are on chronic medication. Around 30 per cent of the diabetics in India, thus making India one of the most coveted markets for Novo Nordisk. As for obesity, at the moment an oral drug – a long-acting once-daily treatment – is in phase-3 clinical trials.

There are two more obesity drugs in phase-1 and phase-2 clinical trials.

